<p>馬里蘭州蓋爾曼鎮，2026 年 4 月 30 日（GLOBE NEWSWIRE）-- Senseonics Holdings, Inc.（納斯達克：SENS）是一家專注於開發、製造和商業化長期植入式連續血糖監測（CGM）系統的醫療科技公司，旨在為糖尿病患者提供服務。今天宣佈以每股 5.00 美元的價格公開發行 8,000,000 股普通股，並向某些投資者提供預先融資的認購權證，以購買 8,000,000 股普通股，購買價格為每股 4.999 美元，該價格等於普通股的公開發行價格減去每個預先融資認購權證的 0.001 美元行使價格。預計 Senseonics 從此次發行中獲得的總收入（在扣除承銷折扣和佣金及估計的發行費用之前）將達到 8000 萬美元。此外，Senseonics 還授予承銷商一個 30 天的選擇權，以在公開發行價格下購買最多 2,400,000 股普通股，扣除承銷折扣和佣金。此次發行預計將於 2026 年 5 月 4 日完成，前提是滿足慣常的交割條件。預先融資的認購權證將不會在任何證券交易所上市。</p>
<p>TD Cowen 和巴克萊銀行擔任此次發行的聯合賬簿管理人，瑞穗銀行和湖街資本擔任賬簿管理人。</p>
<p>此次發行是根據一份 “貨架” 註冊聲明（表格 S-3）進行的，包括於 2025 年 8 月 6 日首次向證券交易委員會（“SEC”）提交併於 2025 年 8 月 18 日生效的基礎招股説明書（文件編號：333-289306）。與此次發行相關的初步招股説明書補充及附帶招股説明書已向 SEC 提交，並可在 SEC 的網站 www.sec.gov 上獲取。與此次發行相關的最終招股説明書補充及附帶招股説明書將向 SEC 提交，並將在 SEC 的網站 http://www.sec.gov 上免費提供。最終招股説明書補充及附帶招股説明書的副本可通過聯繫 TD Securities (USA) LLC，地址為 Broadridge Financial Solutions, 1155 Long Island Avenue, Edgewood, NY 11717，或通過電子郵件聯繫 TDManualrequest@broadridge.com；或聯繫巴克萊資本公司，地址為 Broadridge Financial Solutions, 1155 Long Island Avenue, Edgewood, NY 11717，電話 (888) 603-5847，或通過電子郵件聯繫 barclaysprospectus@broadridge.com。</p>
<p>Senseonics 打算將此次公開發行的淨收益用於資助 Eversense 365 的持續推出和管道產品的開發，以及用於營運資金和一般企業用途。</p>
<p>本新聞稿不構成出售這些證券的要約或購買這些證券的邀請，也不應在任何州或其他司法管轄區進行這些證券的出售，除非在該州或其他司法管轄區的證券法下注冊或合格之前。</p>
<p><strong>關於 Senseonics</strong></p>
<p>Senseonics Holdings, Inc.（&#34;Senseonics&#34;）是一家醫療科技公司，專注於開發、製造和商業化血糖監測產品，旨在通過差異化的長期植入式血糖管理技術改變全球糖尿病社區的生活。Senseonics 的 CGM 系統 Eversense <strong>®</strong> 365 和 Eversense <strong>®</strong> E3 包括一個完全植入皮膚下的小型傳感器，該傳感器與佩戴在傳感器上方的智能發射器進行通信。血糖數據每 5 分鐘自動發送到用户智能手機上的移動應用程序。</p>
<p><strong>前瞻性聲明</strong></p>
<p>本新聞稿包含根據 1995 年《私人證券訴訟改革法》定義的前瞻性聲明，包括但不限於關於 Senseonics 對發行關閉日期的預期以及預計使用發行收益的聲明。&#34;預計&#34;、&#34;潛在&#34;、&#34;可能&#34;、&#34;將&#34;等類似表述旨在識別前瞻性聲明，儘管並非所有前瞻性聲明都包含這些識別詞。實際結果或事件可能因各種重要因素而與這些前瞻性聲明中披露的計劃、意圖和預期大相徑庭，包括與 Senseonics 或承銷商無法滿足發行關閉條件相關的風險；與當前經濟環境、市場及其他條件相關的不確定性；以及在 Senseonics 於 2026 年 3 月 2 日向 SEC 提交的 2025 年 12 月 31 日止年度的 10-K 年度報告的風險因素部分及 Senseonics 不時向 SEC 提交的其他文件中描述的其他風險和不確定性。這些前瞻性聲明中討論的事件和情況可能不會發生，Senseonics 的實際結果可能與預期或暗示的結果大相徑庭且產生不利影響。本新聞稿中包含的任何前瞻性聲明僅代表本日期的觀點，Senseonics 明確不承擔更新任何前瞻性聲明的義務，無論是由於新信息、未來事件還是其他原因。</p>
<p><strong>投資者聯繫：</strong></p>
<p>Jeremy Feffer</p>
<p>LifeSci Advisors</p>
<p>investors@senseonics.com</p>
<p><img src="https://imageproxy.pbkrs.com/https://www.globenewswire.com/newsroom/ti/query-bmY9T1RjeE1USTBNQ00zTlRjM056Y3lJekl5TURNNU16VT0?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://www.globenewswire.com/newsroom/ti/query-bmY9T1RjeE1USTBNQ00zTlRjM056Y3lJekl5TURNNU16VT0"/></p>
<p><img src="https://imageproxy.pbkrs.com/https://ml.globenewswire.com/media/NGUwYTkzYTgtZDlmZS00MzZhLWI4ZTUtYjliYjliZDJiMmU2LTEyMTU0ODgtMjAyNi0wNS0wMS1lbg==/tiny/Senseonics-Holdings-Inc-.png?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://ml.globenewswire.com/media/NGUwYTkzYTgtZDlmZS00MzZhLWI4ZTUtYjliYjliZDJiMmU2LTEyMTU0ODgtMjAyNi0wNS0wMS1lbg==/tiny/Senseonics-Holdings-Inc-.png"/></p>

Senseonics控股

<p>Senseonics 控股公司宣佈以每股 5.00 美元的價格公開發行 800 萬股普通股，融資總額為 8000 萬美元，同時為部分投資者提供預先融資的認股權證。此次發行預計將於 2026 年 5 月 4 日完成，所得款項將用於 Eversense 365 的推出、產品開發和一般企業用途。承銷商包括 TD Cowen 和巴克萊，並提供額外 240 萬股的 30 天選擇權。此次發行是在美國證券交易委員會的貨架註冊聲明下進行的</p>

<p>GERMANTOWN, Md., April 30, 2026 (GLOBE NEWSWIRE) -- Senseonics Holdings, Inc. (NASDAQ: SENS), a medical technology company focused on the development, manufacturing and commercialization of long-term, implantable continuous glucose monitoring (CGM) systems for people with diabetes, today announced the pricing of an underwritten public offering of 8,000,000 shares of common stock at a price to the public of $5.00 per share, and in lieu of common stock, to certain investors, pre-funded warrants to purchase 8,000,000 shares of common stock at a purchase price of $4.999 per pre-funded warrant share, which equals the public offering price per share of the common stock less the $0.001 exercise price per share of each pre-funded warrant. The gross proceeds to Senseonics from the offering, before deducting underwriting discounts and commissions and estimated offering expenses, are expected to be $80 million. In addition, Senseonics granted the underwriters a 30-day option to purchase up to an additional 2,400,000 shares of common stock at the public offering price, less underwriting discounts and commissions. The offering is expected to close on May 4, 2026, subject to satisfaction of customary closing conditions. The pre-funded warrants will not be listed on any securities exchange.</p>
<div class="lb-trans"><p>馬里蘭州蓋爾曼鎮，2026 年 4 月 30 日（GLOBE NEWSWIRE）-- Senseonics Holdings, Inc.（納斯達克：SENS）是一家專注於開發、製造和商業化長期植入式連續血糖監測（CGM）系統的醫療科技公司，旨在為糖尿病患者提供服務。今天宣佈以每股 5.00 美元的價格公開發行 8,000,000 股普通股，並向某些投資者提供預先融資的認購權證，以購買 8,000,000 股普通股，購買價格為每股 4.999 美元，該價格等於普通股的公開發行價格減去每個預先融資認購權證的 0.001 美元行使價格。預計 Senseonics 從此次發行中獲得的總收入（在扣除承銷折扣和佣金及估計的發行費用之前）將達到 8000 萬美元。此外，Senseonics 還授予承銷商一個 30 天的選擇權，以在公開發行價格下購買最多 2,400,000 股普通股，扣除承銷折扣和佣金。此次發行預計將於 2026 年 5 月 4 日完成，前提是滿足慣常的交割條件。預先融資的認購權證將不會在任何證券交易所上市。</p>
</div><p>TD Cowen and Barclays are acting as joint book-running managers and Mizuho and Lake Street are acting as bookrunners for the proposed offering.</p>
<div class="lb-trans"><p>TD Cowen 和巴克萊銀行擔任此次發行的聯合賬簿管理人，瑞穗銀行和湖街資本擔任賬簿管理人。</p>
</div><p>The proposed offering is being made pursuant to a “shelf” registration statement on Form S-3, including a base prospectus (File No. 333-289306) that was originally filed with the Securities and Exchange Commission (the “SEC”) on August 6, 2025 and became effective on August 18, 2025. A preliminary prospectus supplement and accompanying prospectus relating to the proposed offering were filed with the SEC and are available on the SEC’s website at www.sec.gov. A final prospectus supplement and accompanying prospectus relating to the offering will be filed with the SEC and will be available for free on the SEC’s website located at http://www.sec.gov. Copies of the final prospectus supplement and accompanying prospectus may be obtained, when available, by contacting TD Securities (USA) LLC, c/o Broadridge Financial Solutions, 1155 Long Island Avenue, Edgewood, NY 11717, or by email at TDManualrequest@broadridge.com; or Barclays Capital Inc., c/o Broadridge Financial Solutions, 1155 Long Island Avenue, Edgewood, NY 11717, by telephone at (888) 603-5847, or by email at barclaysprospectus@broadridge.com.</p>
<div class="lb-trans"><p>此次發行是根據一份 “貨架” 註冊聲明（表格 S-3）進行的，包括於 2025 年 8 月 6 日首次向證券交易委員會（“SEC”）提交併於 2025 年 8 月 18 日生效的基礎招股説明書（文件編號：333-289306）。與此次發行相關的初步招股説明書補充及附帶招股説明書已向 SEC 提交，並可在 SEC 的網站 www.sec.gov 上獲取。與此次發行相關的最終招股説明書補充及附帶招股説明書將向 SEC 提交，並將在 SEC 的網站 http://www.sec.gov 上免費提供。最終招股説明書補充及附帶招股説明書的副本可通過聯繫 TD Securities (USA) LLC，地址為 Broadridge Financial Solutions, 1155 Long Island Avenue, Edgewood, NY 11717，或通過電子郵件聯繫 TDManualrequest@broadridge.com；或聯繫巴克萊資本公司，地址為 Broadridge Financial Solutions, 1155 Long Island Avenue, Edgewood, NY 11717，電話 (888) 603-5847，或通過電子郵件聯繫 barclaysprospectus@broadridge.com。</p>
</div><p>Senseonics intends to use the net proceeds from the public offering to fund the ongoing launch of Eversense 365 and continued development of pipeline products, as well as for working capital and general corporate purposes.</p>
<div class="lb-trans"><p>Senseonics 打算將此次公開發行的淨收益用於資助 Eversense 365 的持續推出和管道產品的開發，以及用於營運資金和一般企業用途。</p>
</div><p>This press release shall not constitute an offer to sell or the solicitation of an offer to buy these securities, nor shall there be any sale of these securities in any state or other jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or other jurisdiction.</p>
<div class="lb-trans"><p>本新聞稿不構成出售這些證券的要約或購買這些證券的邀請，也不應在任何州或其他司法管轄區進行這些證券的出售，除非在該州或其他司法管轄區的證券法下注冊或合格之前。</p>
</div><p><strong>About Senseonics</strong></p>
<div class="lb-trans"><p><strong>關於 Senseonics</strong></p>
</div><p>Senseonics Holdings, Inc. (&#34;Senseonics&#34;) is a medical technology company focused on the development, manufacturing and commercialization of glucose monitoring products designed to transform lives in the global diabetes community with differentiated, long-term implantable glucose management technology. Senseonics' CGM systems Eversense <strong>®</strong> 365 and Eversense <strong>®</strong> E3 include a small sensor inserted completely under the skin that communicates with a smart transmitter worn over the sensor. The glucose data are automatically sent every 5 minutes to a mobile app on the user's smartphone.</p>
<div class="lb-trans"><p>Senseonics Holdings, Inc.（&#34;Senseonics&#34;）是一家醫療科技公司，專注於開發、製造和商業化血糖監測產品，旨在通過差異化的長期植入式血糖管理技術改變全球糖尿病社區的生活。Senseonics 的 CGM 系統 Eversense <strong>®</strong> 365 和 Eversense <strong>®</strong> E3 包括一個完全植入皮膚下的小型傳感器，該傳感器與佩戴在傳感器上方的智能發射器進行通信。血糖數據每 5 分鐘自動發送到用户智能手機上的移動應用程序。</p>
</div><p><strong>Forward-Looking Statements</strong></p>
<div class="lb-trans"><p><strong>前瞻性聲明</strong></p>
</div><p>This press release contains forward-looking statements within the meaning of The Private Securities Litigation Reform Act of 1995, including without limitation statements regarding, among other things, Senseonics’ expectations about the closing date of the offering and the anticipated use of proceeds from the offering. The words “expects,” “potential,” “may,” “will,” and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. Actual results or events could differ materially from the plans, intentions and expectations disclosed in these forward-looking statements as a result of various important factors, including risks relating to Senseonics’ inability, or the inability of underwriters, to satisfy the conditions to closing for the offering; uncertainties relating to the current economic environment, market and other conditions; and other risks and uncertainties that are described in the Risk Factors section of Senseonics’ Annual Report on Form 10-K for the year ended December 31, 2025, filed with the SEC on March 2, 2026, and other filings Senseonics makes with the SEC from time to time. The events and circumstances discussed in such forward-looking statements may not occur, and Senseonics’ actual results could differ materially and adversely from those anticipated or implied thereby. Any forward-looking statements contained in this press release speak only as of the date hereof, and Senseonics expressly disclaims any obligation to update any forward-looking statements, whether because of new information, future events or otherwise.</p>
<div class="lb-trans"><p>本新聞稿包含根據 1995 年《私人證券訴訟改革法》定義的前瞻性聲明，包括但不限於關於 Senseonics 對發行關閉日期的預期以及預計使用發行收益的聲明。&#34;預計&#34;、&#34;潛在&#34;、&#34;可能&#34;、&#34;將&#34;等類似表述旨在識別前瞻性聲明，儘管並非所有前瞻性聲明都包含這些識別詞。實際結果或事件可能因各種重要因素而與這些前瞻性聲明中披露的計劃、意圖和預期大相徑庭，包括與 Senseonics 或承銷商無法滿足發行關閉條件相關的風險；與當前經濟環境、市場及其他條件相關的不確定性；以及在 Senseonics 於 2026 年 3 月 2 日向 SEC 提交的 2025 年 12 月 31 日止年度的 10-K 年度報告的風險因素部分及 Senseonics 不時向 SEC 提交的其他文件中描述的其他風險和不確定性。這些前瞻性聲明中討論的事件和情況可能不會發生，Senseonics 的實際結果可能與預期或暗示的結果大相徑庭且產生不利影響。本新聞稿中包含的任何前瞻性聲明僅代表本日期的觀點，Senseonics 明確不承擔更新任何前瞻性聲明的義務，無論是由於新信息、未來事件還是其他原因。</p>
</div><p><strong>INVESTOR CONTACT:</strong></p>
<div class="lb-trans"><p><strong>投資者聯繫：</strong></p>
</div><p>Jeremy Feffer</p>
<div class="lb-trans"><p>Jeremy Feffer</p>
</div><p>LifeSci Advisors</p>
<div class="lb-trans"><p>LifeSci Advisors</p>
</div><p>investors@senseonics.com</p>
<div class="lb-trans"><p>investors@senseonics.com</p>
</div><p><img src="https://imageproxy.pbkrs.com/https://www.globenewswire.com/newsroom/ti/query-bmY9T1RjeE1USTBNQ00zTlRjM056Y3lJekl5TURNNU16VT0" alt="" original-src="https://www.globenewswire.com/newsroom/ti?nf=OTcxMTI0MCM3NTc3NzcyIzIyMDM5MzU="/></p>
<p><img src="https://imageproxy.pbkrs.com/https://ml.globenewswire.com/media/NGUwYTkzYTgtZDlmZS00MzZhLWI4ZTUtYjliYjliZDJiMmU2LTEyMTU0ODgtMjAyNi0wNS0wMS1lbg==/tiny/Senseonics-Holdings-Inc-.png" alt="" original-src="https://ml.globenewswire.com/media/NGUwYTkzYTgtZDlmZS00MzZhLWI4ZTUtYjliYjliZDJiMmU2LTEyMTU0ODgtMjAyNi0wNS0wMS1lbg==/tiny/Senseonics-Holdings-Inc-.png"/></p>

Senseonics Announces Pricing of $80 Million Public Offering of Common Stock and Pre-Funded Warrants | SENS Stock News

StockTitan

Senseonics 宣佈 8000 萬美元普通股和預先資助認股權證的公開發行定價 | SENS 股票新聞